Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Michigan: - Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
- Bronson Battle Creek — Battle Creek, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health Medical Center - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Michigan: - Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011) — Grand Rapids, Michigan
Phase 3 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT07007312
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
- Wayne State University School of Medicine — Detroit, Michigan
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Michigan: - Henry Ford Hospital /ID# 270973 — Detroit, Michigan
Phase 2 Recruiting NIH
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- Henry Ford Macomb Hospital-Clinton Township — Clinton Township, Michigan
- Henry Ford Hospital — Detroit, Michigan
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Michigan State University — East Lansing, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Corewell Health Children's — Royal Oak, Michigan
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Bronson Methodist Hospital — Kalamazoo, Michigan
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital — Grand Rapids, Michigan
- Bronson Methodist Hospital — Kalamazoo, Michigan
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Michigan: - Henry Ford Health System Brigitte Harris Cancer Pavillion — Detroit, Michigan
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Michigan: - C.S. Mott University of Michigan — Ann Arbor, Michigan
Phase 2 Recruiting NIH
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute myeloid leukemia…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06917911
Sites in Michigan: - Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Canton — Canton, Michigan
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital — Chelsea, Michigan
- Trinity Health Saint Mary Mercy Livonia Hospital — Livonia, Michigan
- Trinity Health Saint Joseph Mercy Oakland Hospital — Pontiac, Michigan
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Michigan: - Corewell Health ( Site 1001) — Grand Rapids, Michigan
Phase 2 Recruiting Academic/Other
This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the…
Sponsor: University of Alabama at Birmingham
NCT ID: NCT05143840
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
Phase 1, Phase 2 Recruiting Industry
The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the ant…
Sponsor: Debiopharm International SA
NCT ID: NCT06969430
Sites in Michigan: - START Midwest — Grand Rapids, Michigan
Phase 2 Recruiting Academic/Other
This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Ty…
Sponsor: Medical College of Wisconsin
NCT ID: NCT04838041
Sites in Michigan: - The Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Industry
This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04227847
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
- Karmanos Cancer Institute Weisberg Cancer Treatment Center — Farmington Hills, Michigan
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Michigan: - University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Industry
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose c…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06001788
Sites in Michigan: - Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Michigan: - Karmanos Cancer Center — Detroit, Michigan
Phase 1 Recruiting Network
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic…
Sponsor: Children's Oncology Group
NCT ID: NCT06247787
Sites in Michigan: - C S Mott Children's Hospital — Ann Arbor, Michigan
Phase 1 Recruiting Industry
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell N…
Sponsor: Imugene Limited
NCT ID: NCT03666000
Sites in Michigan: - Barbara Ann Karmanos Cancer Institute (Wayne State University) — Detroit, Michigan
Phase 1 Recruiting Industry
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and t…
Sponsor: SillaJen, Inc.
NCT ID: NCT05768932
Sites in Michigan: - University of Michigan — Ann Arbor, Michigan
Phase 1 Recruiting Industry
CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is…
Sponsor: MacroGenics
NCT ID: NCT05362773
Sites in Michigan: - START - Midwest — Grand Rapids, Michigan
EARLY Phase 1 Recruiting Academic/Other
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymph…
Sponsor: New York Medical College
NCT ID: NCT03719105
Sites in Michigan: - Helen De Vos — Grand Rapids, Michigan
Phase 1 Recruiting Academic/Other
This phase I trial tests the safety and effectiveness of pomalidomide after CD19 chimeric antigen receptor T-cell (CD19CART) therapy for the treatment of patients with CD19+ B-cell leukemias or lymphomas that have come back after a period …
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT07532525
Sites in Michigan: - University of Michigan Rogel Cancer Center — Ann Arbor, Michigan